



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

Lupin announces settlement with Warner Chilcott of Loestrin[®] 24 Fe and Femcon[®] Fe Patent Litigations

Mumbai, October 14, 2010: Pharma Major, Lupin Ltd. announced today that it and Warner Chilcott plc and its subsidiary, Warner Chilcott Company, LLC have entered into a settlement agreement to resolve pending patent litigations involving Warner Chilcott's oral contraceptive products, Loestrin[®] 24 Fe and Femcon[®] Fe.

Under the terms of the Settlement Agreement, Lupin has agreed that, except in the event of an at-risk launch of a generic Loestrin[®] 24 Fe product by a third-party, neither Lupin nor its affiliates will market or sell a generic Loestrin[®] 24 Fe product prior to July 22, 2014. In the event of such an at-risk launch by Lupin, Warner Chilcott has reserved its right to bring an infringement suit against Lupin and pursue all legally available remedies.

In addition, Lupin has been granted a non-exclusive license by Warner Chilcott covering Femcon[®] Fe, which will permit Lupin to commence marketing either an authorized generic product, which would be supplied by Warner Chilcott, or generic equivalent of Femcon[®] Fe in the United States beginning on the earlier of (1) 180 days after the date that Teva Pharmaceutical Industries, Ltd enters the market with a generic equivalent to Femcon[®] Fe, or (2) January 1, 2013.

Lupin has also been granted rights to purchase and sell in the United States an authorized generic version of the Asacol[®] 400 mg product, which would be supplied by Warner Chilcott, only if a generic version of the Asacol[®] 400 mg product is launched by a third party in the United States.

The final settlement remains subject to certain conditions specified in the Settlement Agreement, including the Court's ordering the stipulations of dismissal.

About Lupin Limited

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 8th by prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest

growing, top 5 pharmaceutical players in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY - IMS) as well as the Philippines.

For the Financial Year 2009-10, Lupin's Consolidated Revenues and Profit after Tax were Rs. 47,678 million (USD 1.1 Billion) and Rs. 6,186 million (USD 152 million) respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

For further information please contact:

Shamsher Gorawara
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

OR

Sonia Mansata
Text 100 Public Relations
Ph: +91 98 20 11 2481
Email: sonia.mansata@text100.co.in

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.